Abstract
In the pre-era of synthetic antibodies, pharmaceutical companies depended on finding novel drugs from medicinal plants and other traditional resources; while at present, technological advances in biology, computer, and robotics give researchers the ability to rewrite and edit DNA to synthesize extensive sets of drug candidates; these novel and improved candidates serve the basis for creating another library of drug candidates and so on until we find the right biomolecule for the disease of interest. All these technologies combined to synthesize therapeutic antibodies for many types of cancer, autoimmune diseases, and infectious diseases that can address diseases much more readily to very rapidly get therapeutics into patients so that we can potentially impact disease. The antibody mechanism is recognized, binds to disease cells, and pinpoints the immune system to attack those cells effectively. Now a day, they depend on a computational approach to guide and accelerate the process of antibodies engineering by a combination of a selection system and the use of high-throughput data acquisition and analysis to build and construct populations of next-generation antibodies that are thermo-stable, non-immunogenic as possible, and to be administered to many humans as possible. In this review, I will discuss the latest in silico methods for antibody engineering.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.